MaxCyte announces acquisition of SeQure Dx

(Sharecast News) - MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services for cell and gene therapies, in a move aimed at broadening its offerings in the cell engineering space.

The AIM-traded firm said the acquisition would strengthen its ability to serve both ex vivo and in vivo cell and gene therapy developers by expanding its suite of tools and services from early research through to clinical development and commercialization.

It said the integration of SeQure Dx would enable the company to engage with therapy developers earlier in the research process, leveraging its commercial and field application scientist teams to provide advanced editing assessment capabilities.

SeQure Dx was already revenue-generating, and was expected to contribute to MaxCyte's overall revenue growth.

As regulatory requirements for cell and gene therapies continued to focus on safety, the ability to precisely assess gene editing outcomes was becoming increasingly critical, MaxCyte explained.

It said SeQure Dx's expertise in confirming editing accuracy and assessing off-target effects across both viral and non-viral gene editing modalities enhances MaxCyte's position in the market.

The acquisition would support the standardisation of cell engineering workflows, providing developers with more comprehensive process development capabilities, MaxCyte explained.

"This acquisition underscores MaxCyte's commitment to providing CGT developers with cutting-edge tools to address complex cell engineering challenges," said chief executive officer Maher Masoud.

"Integrating SeQure Dx into MaxCyte's portfolio will allow us to leverage our scientific support and complementary offerings to drive advancements in the safety and precision of cell therapies.

"At MaxCyte, we see tremendous opportunity to transform cell and gene engineering with world-class tools and solutions and will continue to make organic and inorganic growth investments to position the Company as an end-to-end cell and gene engineering solutions provider."

At 1535 GMT, shares in MaxCyte were up 0.53% at 377p.

Reporting by Josh White for Sharecast.com.